Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains.

Chen H, Liu Y, Zhao C, Xiao D, Zhang J, Zhang F, Chen M, Wang H.

PLoS One. 2013 Jun 28;8(6):e66880. doi: 10.1371/journal.pone.0066880.

2.

Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK.

Antimicrob Agents Chemother. 2006 Sep;50(9):3039-47.

3.

DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.

Cui L, Lian JQ, Neoh HM, Reyes E, Hiramatsu K.

Antimicrob Agents Chemother. 2005 Aug;49(8):3404-13.

4.
5.

High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.

Wang JL, Lai CH, Lin HH, Chen WF, Shih YC, Hung CH.

Int J Antimicrob Agents. 2013 Nov;42(5):390-4. doi: 10.1016/j.ijantimicag.2013.07.010.

PMID:
24041465
6.

[The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].

Feng NN, Wang Q, Song YL, He LX, Zhou CM, Xie HM, Li HY.

Zhonghua Nei Ke Za Zhi. 2013 Apr;52(4):318-22. Chinese.

PMID:
23925360
7.

Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.

Hu HC, Kao KC, Chiu LC, Chang CH, Hung CY, Li LF, Liu TP, Lin LC, Chen NH, Huang CC, Yang CT, Lu JJ.

BMC Infect Dis. 2015 Oct 23;15:444. doi: 10.1186/s12879-015-1215-2.

8.

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.

Katayama Y, Murakami-Kuroda H, Cui L, Hiramatsu K.

Antimicrob Agents Chemother. 2009 Aug;53(8):3190-6. doi: 10.1128/AAC.00834-08.

9.

Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.

Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM.

J Antimicrob Chemother. 2010 Apr;65(4):725-8. doi: 10.1093/jac/dkq028.

PMID:
20139142
11.

Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

van Hal SJ, Paterson DL.

Antimicrob Agents Chemother. 2011 Jan;55(1):405-10. doi: 10.1128/AAC.01133-10. Review.

12.

Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.

Cafiso V, Bertuccio T, Spina D, Purrello S, Campanile F, Di Pietro C, Purrello M, Stefani S.

PLoS One. 2012;7(1):e29573. doi: 10.1371/journal.pone.0029573.

13.

Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.

Leonard SN, Rossi KL, Newton KL, Rybak MJ.

J Antimicrob Chemother. 2009 Mar;63(3):489-92. doi: 10.1093/jac/dkn520.

PMID:
19136530
14.

Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.

Richter SS, Satola SW, Crispell EK, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Diekema DJ, Doern GV.

J Clin Microbiol. 2011 Dec;49(12):4203-7. doi: 10.1128/JCM.01152-11.

15.
16.

Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.

Yamakawa J, Aminaka M, Okuzumi K, Kobayashi H, Katayama Y, Kondo S, Nakamura A, Oguri T, Hori S, Cui L, Ito T, Jin J, Kurosawa H, Kaneko K, Hiramatsu K.

J Infect Chemother. 2012 Jun;18(3):406-9. doi: 10.1007/s10156-011-0330-2.

PMID:
22033576
17.
18.

Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.

Lin SY, Chen TC, Chen FJ, Chen YH, Lin YI, Siu LK, Lu PL.

J Microbiol Immunol Infect. 2012 Dec;45(6):435-41. doi: 10.1016/j.jmii.2012.05.004.

19.

Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.

Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ.

Antimicrob Agents Chemother. 2009 Feb;53(2):805-7. doi: 10.1128/AAC.01009-08.

20.

Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains.

Méhes L, Taskó S, Székely A, Tóth A, Ungvári E, Erdei I, Dombrádi Z, Szabó J, Maródi L.

J Med Microbiol. 2012 Feb;61(Pt 2):198-203. doi: 10.1099/jmm.0.029421-0.

PMID:
21959204

Supplemental Content

Support Center